INTRODUCTION {#S1}
============

The translation of clinically relevant biomarkers into personalized medicine for colorectal cancer (CRC) patients has proven a challenging endeavor. For instance, while RAS mutant status predicts lack of response towards epidermal growth factor receptor (EGFR) directed antibodies\[[@R1]--[@R4]\], many patients with RAS wild-type tumors do not benefit from such therapy\[[@R5]--[@R7]\]. Similarly, the predictive utility of EGFR\[[@R3], [@R8]--[@R10]\] expression and the V600E BRAF mutation\[[@R11], [@R12]\] has been limited, and studies evaluating the predictive value of VEGFR2\[[@R13], [@R14]\] expression for vascular endothelial growth factor (VEGF) targeted drugs have yielded inconsistent results. Likewise, molecular determinants of response towards cytotoxic agents, including fluoropyrimidines (i.e. thymidylate synthase \[TS\]) and platinum agents (i.e. excision repair cross complement group 1 \[ERCC1\]), have been retrospectively associated with response rates and survival\[[@R15]--[@R18]\] but are not yet prospectively validated. Limitations impeding biomarker development include methodological differences across studies, redundancy in signaling as well as tumor heterogeneity.

Recent data suggests that the location of a colorectal tumor (i.e. proximal vs. distal colon vs. rectum) may impact its molecular landscape\[[@R19], [@R20]\] and clinical behavior\[[@R21], [@R22]\]. Microarray DNA analyses have revealed over 1,000 genes with different expression patterns between ascending and descending colon cancers\[[@R23]\], which partly reflect the distinct embryonic origin (i.e. midgut vs. hindgut) and vascular supply (i.e. superior vs. inferior mesenteric artery) of the proximal and distal colon\[[@R24]\]. Phenotypically, proximal tumors are prone to microsatellite instability\[[@R25], [@R26]\], BRAF mutations\[[@R27], [@R28]\] and poorly differentiated histology\[[@R29], [@R30]\], whereas distal tumors are characterized by loss of heterozygosity and *TP53* mutations\[[@R29], [@R30]\]. Clinically, proximal tumors tend to present at later stages\[[@R31]\] and are associated with worse overall survival\[[@R32]\] relative to their distal counterparts.

Though the presence of anatomic based CRC gene signatures has been established, associations between predictive and prognostic biomarker expression and tumor location are not well understood. Such knowledge may shed insight on interactions linking tumor location and treatment response and outcomes which may guide personalized therapy in the future. On this premise, we used a commercially available database to determine the relationship between primary tumor site and the expression of biomarkers involved in major signaling pathways in advanced CRC patients. Specifically, we examined the associations between tumor location and gene expression levels of proteins involved in tumor growth (EGFR), angiogenesis (VEGFR2), DNA repair (ERCC1) and chemotherapy drug metabolism (TS) as well as KRAS and BRAF mutation status.

MATERIALS AND METHODS {#S2}
=====================

Study Design and Patient Population {#S3}
-----------------------------------

We conducted a retrospective analysis of data collected from a cohort of 578 patients with stage IV colorectal cancer, whose tumor tissue was submitted to Response Genetics Incorporated (Los Angeles, CA), a CLIA certified and CAP accredited laboratory, for comprehensive molecular testing (ColonDX™). Patient samples were submitted from both private and academic healthcare institutions across the United States between 2007 and 2010. Formalin-fixed paraffin embedded (FFPE) tumor specimens were tested for KRAS and BRAF mutation status, as well as mRNA expression levels of ERCC1, TS, EGFR and VEGFR2. Only patients whose specimens had sufficient tissue for analysis of at least one gene of interest (i.e. ERCC1, TS, EGFR, VEGFR2) and detection of either KRAS and/or BRAF mutations, as well as data regarding patient and tumor characteristics were included in this study. Tumor samples from metastatic sites, in which the primary tumor location was unknown, were excluded. A total of 431 patients were included in the final analysis.

Information regarding primary tumor location, patient age and gender, tumor grade and histology, were extracted from pathology reports submitted with the tissue specimens and recorded by two of the authors (M. K. M., D. L. H.). Specifically, the splenic flexure was used to distinguish proximal from distal tumors. Tumors within 15 cm of the anal verge were designated as originating in the rectum.

Tumor Tissue Preparation and Gene Expression Analysis {#S4}
-----------------------------------------------------

Tumor tissue from study patients was obtained at the time of diagnosis prior to surgery and at the time of surgical resection. Hematoxylin and eosin (H&E) stained sections of all FFPE specimens were evaluated by a board certified pathologist for tumor content.

Formalin-fixed paraffin-embedded tissues were dissected. Ten-micrometer-thick slides were obtained from the identified areas with the highest tumor concentration and were mounted on uncoated glass slides. For histologic diagnosis, three sections representative of the beginning, middle, and end of the tissue were stained with H&E, using the standard method. Before microdissection, sections were de-paraffinized in xylene for 10 minutes, hydrated with 100%, 95%, and 70% ethanol, and then washed in H2O for 30 seconds. Following microdissection of tumor cells, the sections were stained with nuclear fast red (American Master Tech Scientific, Inc.) for 20 seconds and rinsed in water for 30 seconds. Samples were then dehydrated with 70%, 95%, and 100% ethanol for 30 seconds each, followed by xylene for 10 min. The slides were then completely air-dried. Laser capture microdissection (PALM Microlaser Technologies AG) was carried out in all tumor samples to ensure that only tumor cells were dissected\[[@R33]\]. The dissected particles of tissue were transferred to a reaction tube containing 400 mL of RNA buffer for lysis of tumor cells.

After lysis of the tumor cells, RNA and DNA were isolated separately from the specimen. RNA isolation from paraffin-embedded samples was done according to a proprietary procedure defined by Response Genetics, Inc. (US Patent \#6248535). The RNA was then reverse-transcribed to cDNA as described previously\[[@R34]\]. DNA was either directly extracted or back extracted from the organic phase, both with an RGI patented method (US Patent \#6248535).

Quantitation of gene mRNA expression levels of ERCC1, TS, EGFR, VEGFR2, and an internal reference (β-actin) cDNA was done using a fluorescence-based real-time detection method \[ABI PRISM 7900 Sequence detection System (TaqMan); Perkin-Elmer Applied Biosystem\] as previously described(43)\[[@R35]\]. Isolated RNA was reverse-transcribed to cDNA, followed by RT-PCR using specific primers and probes. The PCR reaction mixture consisted of 1,200 nmol/L of each primer, a 200 nmol/L probe, 0.4 U of AmpliTaq Gold Polymerase, 200 nmol/L of dATP, dCTP, dGTP, dTTP; 3.5 mmol/L MgCl2, and 1X TaqMan Buffer A containing a reference dye added to a final volume of 20 mL (all reagents from PE Applied Biosystems). Cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, followed by 46 cycles at 95°C for 15 seconds and 60°C for 1 minute.

The ERCC1 primers and probe sequences used were as follows: forward primer, GGGAATTTGGCGACGTAATTC; reverse primer, GCGGAGGCTGAGGAACAG; probe, 6FAM-CACAGGTGCTCTGGCCCAGCACATA. The TS primers and probe sequences used were as follows: forward primer, GCCTCGGTGTGCCTTTCA; reverse primer, CCCGTGATGTGCGCAAT; probe, 6FAM-TCGCCAGCTACGCCCTGCTCA. The EGFR primers and probe sequences used were as follows: forward primer, TGCGTCTCTTGCCGGAAT; reverse primer GGCTCACCCTCCAGAAGGTT; probe, 6FAM-ACGCATTCCCTGCCTCGGCTG. The VEGFR2 primers and probe sequences used were as follows: forward primer, CCTGTGG CTCTGCGTGGA; reverse primer, CTGAGCCTGGGCAGAT CAAG; probe, 6FAM-CACTAGGCAAACCCACAGAGGCGGC. The β-actin primers and probe sequences used were as follows: forward primer, GAGCGCGGCTACAGCTT; reverse primer, TCCTTAATGTCACGCACGATTT; probe, 6FAM-ACCACCACGGCCGAGCGG.

For each sample, parallel TaqMan PCR reactions were carried out for each gene of interest and the β-actin reference gene to normalize for input cDNA. Results were obtained as a ratio of the PCR fluorescent signals of each gene of interest relative to the reference gene, β-actin.

KRAS mutation analysis was performed with a Response Genetics Inc. (RGI) designed mutation assay by RT-PCR using specifically designed primers and probes to detect each of the following mutations: Gly12Ala (GGT\>GCT) 522; Gly12Asp (GGT\>GAT) 521; Gly12Arg (GGT\>CGT) 518; Gly12Cys (GGT\>TGT) 516; Gly12Ser (GGT\>AGT) 517; Gly12Val (GGT\>GTT) 520; Gly13Asp (GGC\>GAC) 532. After RT-PCR, all collected data was analyzed through an RGI Excel™ template and according to delta-CT values the mutation status was established. BRAF V600E mutations were detected by dye terminator sequencing.

Statistical Analysis {#S5}
--------------------

Messenger RNA expression levels of ERCC1, TS, EGFR, and VEGFR2 were summarized and analyzed by Wilcoxon two-sample tests to detect differences based on KRAS and BRAF mutation status within each tumor site. Pairwise differences between the expression of the four examined genes across tumor sites, independent of KRAS and BRAF mutation status, were then determined by Wilcoxon two-sample tests, with significance determined by Kruskal-Wallis testing. Bonferroni method was used to correct *p* value for multiple comparisons. All values were reported as medians and ranges, with a significance p-value cutoff ≤ 0.05. Analyses were performed using Statistical Analysis Software (SAS) version 9.3 (SAS Institute Inc. NC, USA).

RESULTS {#S6}
=======

Patient and Tumor Characteristics {#S7}
---------------------------------

Among 431 patients with advanced CRC, 58% were men and 42% were women, with a median age of 61 years (range 27--92 years old) ([Table 1](#T1){ref-type="table"}). The distribution of tumor site was as follows: 39% distal, 40% proximal, and 21% rectal. The frequency of KRAS and BRAF mutations amongst all patients was 42% and 8%, respectively. BRAF mutations were significantly more common in the proximal colon (14%), followed by distal colon (5%) and rectal tumors (2%) (p\<0.001), whereas KRAS mutations occurred at similar frequencies throughout the colorectum (p=0.51) ([Table 1](#T1){ref-type="table"}).

ERCC1 Expression by Tumor Location and KRAS, BRAF Mutation Status {#S8}
-----------------------------------------------------------------

Rectal cancers demonstrated higher ERCC1 expression (median 1.11 \[0.23--4.23\]) than either distal (median 0.83 \[0.17--6.66\]) or proximal colon tumors (median 0.91 \[0.26--3.06\]) (p=0.001) ([Figure 1A](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

Among all patients, KRAS mutant status was associated with decreased ERCC1 expression (median 0.87 \[0.23--2.96\]) compared to KRAS wild-type status (median 0.97 \[0.17--6.66\]) (p=0.01) ([Table 3](#T3){ref-type="table"}). In subgroup analysis, this trend remained significant in proximal tumors (KRAS mutant median 0.82 \[0.26--2.95\]; KRAS wildtype median 0.98 \[0.28--3.06\]; p=0.005) ([Table 2](#T2){ref-type="table"}). A similar trend was seen in rectal tumors but did not reach statistical significance (KRAS mutant median 0.96 \[0.23--2.60\]; KRAS wildtype median 1.25 \[0.37--4.23\]; p=0.052) ([Table 2](#T2){ref-type="table"}).

There was no significant association between BRAF mutation status and ERCC1 expression ([Table 3](#T3){ref-type="table"}). In the subgroup of proximal tumors (n=156), there was a non-significant trend towards increased ERCC1 expression in BRAF mutant tumors (median 0.96 \[0.28--2.47\]) compared to BRAF wildtype tumors (median 0.88 \[0.26--3.06\]) (p=0.06).

TS Expression by Tumor Location and KRAS, BRAF Mutation Status {#S9}
--------------------------------------------------------------

Rectal tumors had significantly higher TS expression levels (median 2.60 \[0.77--21.43\]) than distal colon cancers (median 2.12 \[0.65--10.26\]) (p=0.02) ([Figure 1B](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). There were no other differences detected in TS expression between tumor sites.

Patients with KRAS mutant tumors had significantly lower TS mRNA levels (median 2.08 \[0.52--21.43\]) than those with KRAS wild-type cancers (median 2.38 \[0.65--18.99\]) (p=0.03) ([Table 3](#T3){ref-type="table"}). When stratified by tumor location, this association remained significant only in proximal colon tumors (KRAS mutant median 1.90 \[0.52--9.43\]; KRAS wildtype median 2.38 \[0.65--13.81\]; p=0.03) ([Table 2](#T2){ref-type="table"}).

The BRAF V600E mutation was predictive of increased TS levels (BRAF mutant median 3.38 \[1.01--13.81\]; BRAF wildtype median 2.17 \[0.52--21.43\]; p\<0.001) among all patients ([Table 3](#T3){ref-type="table"}). This association remained significant in proximal colon tumors (BRAF mutant median 3.68 \[1.01--13.81\]; BRAF wildtype median 2.07 \[0.52--11.10\]; p=0.003) ([Figure 2A](#F2){ref-type="fig"}).

EGFR Expression by Tumor Location and KRAS, BRAF Mutation Status {#S10}
----------------------------------------------------------------

EGFR expression was similar across all tumor sites (p=0.20; [Figure 1C](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}). However, EGFR expression was decreased in KRAS mutated cancers (median 1.61 \[0.33--7.17\]) compared to KRAS wildtype cancers (median 2.06 \[0.63--71.28\]) (p\<0.001) among all patients ([Table 3](#T3){ref-type="table"}). In subgroup analysis, this difference remained significant in proximal colon cancers (KRAS mutant median 1.60 \[0.33--7.17\]; KRAS wildtype median 2.12 \[0.63--7.45\]; p\<0.001) ([Table 2](#T2){ref-type="table"}).

BRAF mutant status was associated with increased EGFR levels across all patients (BRAF mutant median 2.20 \[1.12--3.50\]; BRAF wildtype median 1.75 \[0.33--71.28\]; p=0.002) ([Table 3](#T3){ref-type="table"}). This association remained significant in the proximal colon cohort (BRAF mutant median 2.23 \[1.45--3.50\]; BRAF wildtype median 1.76 \[0.33--7.45\]; p=0.002) ([Figure 2B](#F2){ref-type="fig"}).

VEGFR2 Expression by Tumor Location and KRAS, BRAF Mutation Status {#S11}
------------------------------------------------------------------

Rectal tumors demonstrated significantly higher VEGFR2 expression (1.77 \[0.23--13.00\]) than distal (1.24 \[0.18--7.66\]) and proximal (1.10 \[0.24--6.10\]) tumors (p\<0.001 for both comparisons; [Figure 1D](#F1){ref-type="fig"}, [Table 2](#T2){ref-type="table"}).

Furthermore, VEGFR2 mRNA levels were significantly lower in mutated KRAS tumors (median 1.19 \[0.23--7.66\]) than in wild-type tumors (median 1.35 \[0.18--13.00\]) (p=0.003) ([Table 3](#T3){ref-type="table"}). In subgroup analysis, this relationship persisted in proximal (KRAS mutant median 0.91 \[0.24--6.10\]; KRAS wildtype median 1.29 \[0.33--5.94\]; p=0.01) and rectal (KRAS mutant median 1.53 \[0.23--3.62\]; KRAS wildtype median 2.21 \[0.37--13.00\]; p=0.02) cancers ([Table 2](#T2){ref-type="table"}).

There was no significant association between BRAF mutation status and VEGFR2 expression ([Table 3](#T3){ref-type="table"}). In subgroup analysis, proximal tumors (n=106) with the BRAF V600E mutation trended towards increased VEGFR2 expression (median 1.48 \[0.56--2.63\]) compared to BRAF wildtype tumors (median 1.06 \[0.24--6.10\]) (p=0.07).

DISCUSSION {#S12}
==========

Colorectal cancer subsites are characterized by distinct genetic and histopathological features, but the association between tumor location and prognostic and predictive biomarker expression is not well delineated. We evaluated whether primary tumor site influences KRAS and BRAF mutation status and the mRNA expression of biomarkers reflecting DNA repair, fluoropyrimidine metabolism, tumor cell growth, and angiogenesis in advanced CRC. Our analysis revealed that each tumor site has a unique molecular phenotype which may predict chemotherapeutic and antibody drug sensitivity as well as clinical outcomes ([Figure 3](#F3){ref-type="fig"}). Furthermore, we found that KRAS and BRAF mutation status is associated with biomarker gene expression, and these relationships depend upon tumor location.

KRAS and BRAF Mutation Status by Tumor Location {#S13}
-----------------------------------------------

The distribution of KRAS mutations was similar across tumor sites. While others\[[@R36]--[@R38]\] have demonstrated more frequent KRAS mutations in the proximal colon, the data are not consistent\[[@R39]\], and this may reflect methodologic variation as well as different KRAS mutations being examined between studies. Conversely, BRAF V600E mutations were more common in proximal cancers in our cohort, which is consistent with prior data\[[@R12], [@R28], [@R37]\]. The predilection of BRAF mutations for the proximal colon partly reflects increased microsatellite instability (MSI) in this region\[[@R26], [@R40], [@R41]\], as microsatellite unstable tumors are more enriched with BRAF mutations\[[@R42], [@R43]\].

ERCC1, TS, EGFR, and VEGFR2 Expression by Tumor Location {#S14}
--------------------------------------------------------

Though prior investigations have demonstrated divergent patterns of gene expression, metastatic spread, and response to therapy between rectal and colonic tumors\[[@R28], [@R37]\], ours is the first study to reveal anatomic-based differences in ERCC1 and VEGFR2 expression. Irrespective of KRAS or BRAF mutation status, rectal cancers had significantly higher ERCC1 and VEGFR2 mRNA levels compared to distal and proximal colon tumors, in addition to increased TS levels compared to distal colon cancers. Our group and others have previously shown contrasting TS expression patterns by CRC subsite\[[@R44]--[@R46]\], though the different assays used (i.e. enzymatic vs. nuclear or cytoplasmic protein expression) confounds interpretation. In sum, our findings suggest that the efficacy of oxaliplatin, anti-angiogenic, and fluoropyrimidine agents may differ between proximal and distal tumors, and this hypothesis warrants prospective validation in the clinical trial setting. Furthermore, stratification by specific anatomic site (rather than broad categories of proximal vs. distal tumors) may offer more useful predictive and prognostic information\[[@R37]\].

Influence of KRAS and BRAF Mutation Status on ERCC1, TS, EGFR, and VEGFR2 Expression Depends on Tumor Location {#S15}
--------------------------------------------------------------------------------------------------------------

Mutant KRAS status was associated with lower expression of ERCC1, TS, EGFR, and VEGFR2 among all patients. In multivariate analysis, this association remained significant for all biomarkers in the proximal colon. In addition, among rectal cancers, KRAS mutant tumors had decreased VEGFR2 expression than KRAS wildtype ones. That the association between KRAS status and biomarker gene expression varied by tumor location supports distinct carcinogenic mechanisms across tumor sites. It also suggests the presence of a heterogeneous intestinal microenvironment, and that tumor-stromal interactions and epigenetic modifications are critical in mediating the effects of cytotoxic and targeted agents.

One such epigenetic association may exist between the KRAS and nucleotide excision repair (NER) pathways, particularly in proximal colonic tumors. *In vitro* studies in COLO320DM colon cancer cell lines\[[@R47]\] have demonstrated that KRAS suppression by small interfering RNAs (siRNAs) leads to ERCC1 overexpression and oxaliplatin resistance, whereas KRAS activation may decrease ERCC1 gene expression through upregulation of DNA methyltransferase 3 beta (DNMT3B) and subsequent ERCC1 hypermethylation, promoting oxaliplatin sensitivity\[[@R47]\]. It follows that one anatomic-based link between KRAS and NER may lie in methylation differences between tumor sites. The CpG island methylator phenotype (CIMP) is more common in proximal\[[@R48], [@R49]\] and KRAS-mutant\[[@R50]\] tumors. Our findings may also help explain clinical outcome data from the PRIME\[[@R51]\] and OPUS\[[@R52]\] trials. Patients from these studies with KRAS mutant tumors who were treated with FOLFOX alone showed a trend towards improved progression-free survival, relative to those with KRAS wildtype tumors. Such a relationship was not observed in the CRYSTAL trial\[[@R53]\] which used irinotecan-based chemotherapy. Identifying the regulatory mechanisms between KRAS activation, NER, and tumor location may offer novel and more personalized drug targets in future investigations.

TS expression was also influenced by KRAS and BRAF mutation status in a location-dependent manner. The lower TS mRNA levels in KRAS mutated proximal colon tumors suggest increased fluoropyrimidine sensitivity in this cohort. Previous studies have not shown a significant association between KRAS mutation status and response to fluoropyrimidines\[[@R54]\] or TS expression\[[@R54]--[@R56]\] regardless of tumor location, though these studies employed enzymatic rather than mRNA assays, which limits direct comparison with our results. In contrast, the BRAF V600E mutation was associated with increased TS expression among proximal cancers. This may provide a potential explanation for the inferior outcomes seen in patients with BRAF-mutated tumors treated with 5-FU based regimens\[[@R57]\]. Both CIMP\[[@R58], [@R59]\] and MSI\[[@R60], [@R61]\] status have also been independently linked with lack of clinical benefit from 5-FU, though examinations of the predictive utility of CIMP\[[@R62]\] and MSI\[[@R63], [@R64]\], and the correlation between MSI and TS expression\[[@R65]--[@R70]\] have yielded conflicting data. As such, further studies are needed to better define the relationship between methylation patterns, mismatch repair, and TS expression in proximal tumors.

Among proximal colon cancers, KRAS mutated tumors had significantly decreased EGFR and VEGFR2 levels, compared to wildtype tumors. These findings suggest that in addition to constitutive KRAS activation, downregulation of EGFR and angiogenic pathways may provide another reason for diminished response towards targeted antibodies in these patients. Indeed, in a recent subgroup analysis of the FIRE-3 trial\[[@R71]\], patients with proximal tumors benefited less from anti-EGFR directed therapies than those with distal cancers. It also suggests that the EGFR and VEGF signaling pathways share regulatory pathways\[[@R72]\], including the MAPK/PI3K, STAT3 and hypoxia-inducible factor (HIF) signaling cascades, as demonstrated in cell line and xenograft models\[[@R73]\]. Within the rectal cancer cohort, KRAS mutant tumors had decreased VEGFR2 expression compared to the KRAS wildtype group. This is consistent with clinical data showing significantly improved pathologic complete response rates among KRAS wildtype rectal cancer patients receiving cetuximab-based neoadjuvant chemoradiation, and whose tumors had increased intratumoral VEGFR2 expression\[[@R74]\].

In contrast to KRAS mutant tumors, BRAF mutated cancers had increased EGFR expression in the proximal colon subgroup. As our samples came from un-treated patients, this supports the hypothesis that EGFR overexpression may be an inherent rather than acquired resistance mechanism towards BRAF inhibitors\[[@R75], [@R76]\] in CRC patients.

Our study has its limitations, the first of which is its retrospective design. We could not account for potential confounding variables, including history of prior cancers, patient ethnicity, and MSI status, any of which could have independently influenced biomarker expression. An extended RAS analysis examining mutations outside of exon 2 may have yielded additional associations between tumor location and gene expression. Furthermore, information regarding prior treatment, particularly in patients who may have had liver-limited metastases and received chemotherapy prior to surgical resection is not known. In addition, we used the splenic flexure as the dividing line between proximal and distal sided tumors since the precise location of tumors within the transverse colon (i.e. proximal two-thirds vs. distal one-third) was not always documented, and this does not reflect boundaries based on blood supply and embryonic origin. Importantly, the lack of outcome data precludes definitive conclusions about the prognostic significance of the demonstrated anatomic-based associations in gene expression.

CONCLUSIONS {#S16}
===========

Colorectal cancer comprises a spectrum of tumors with unique carcinogenic mechanisms, stromal interactions, and clinical outcomes based on primary site. Our study is the first to demonstrate that the mRNA expression of predictive and prognostic biomarkers and their relationship with KRAS and BRAF mutation status are contingent on anatomic location. Our analysis further emphasizes the distinct biology among colorectal cancers and that tumor location should be included in clinical decision-making. Prospective studies ought to confirm our findings and incorporate the role of tumor site in understanding CRC molecular heterogeneity and evolving phenotypes with treatment. A more refined use of biomarkers should advance clinical trial design, drug development, and patient outcomes.
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A: ERCC1 Expression by Tumor Location

\* Based on Wilcoxon two - sample test for pairwise differences by two tumor sites adjusting for multiple comparisons.

B: TS Expression by Tumor Location

\* Based on Wilcoxon two - sample test for pairwise differences by two tumor sites adjusting for multiple comparisons.

C: EGFR Expression by Tumor Location

\* Based on Wilcoxon two - sample test for pairwise differences by two tumor sites adjusting for multiple comparisons.

D: VEGFR2 Expression by Tumor Location

\* Based on Wilcoxon two - sample test for pairwise differences by two tumor sites adjusting for multiple comparisons.
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A: TS Expression by BRAF Mutation Status in Proximal Colon Cancers

B: EGFR Expression by BRAF Mutation Status in Proximal Colon Cancers
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Colorectal Cancer Patient and Tumor Characteristics (N = 431)

                                    Primary Tumor Location[\*](#TFN1){ref-type="table-fn"}                               
  --------------------------------- -------------------------------------------------------- ------------- ------------- -------------
  **Age in Years** median (range)   59 (27--92)                                              66 (29--89)   59 (31--85)   **\<0.001**
                                                                                                                         
  **Gender**                                                                                                             0.09
  Men                               97 (57%)                                                 92 (54%)      61 (68%)      
  Women                             73 (43%)                                                 79 (46%)      29 (32%)      
                                                                                                                         
  **Tumor Grade**                                                                                                        **0.04**
      Well Differentiated           7 (4%)                                                   10 (6%)       8 (9%)        
      Moderately Differentiated     106 (62%)                                                88 (51%)      52 (58%)      
      Poorly Differentiated         31 (18%)                                                 48 (28%)      14 (16%)      
      Unknown                       26 (15%)                                                 25 (15%)      16 (18%)      
                                                                                                                         
  **KRAS Mutation Status**                                                                                               0.51
      Mutant                        69 (41%)                                                 78 (46%)      33 (37%)      
      Wildtype                      91 (54%)                                                 83 (49%)      46 (51%)      
      Unknown                       10 (6%)                                                  10 (6%)       11 (12%)      
                                                                                                                         
  **KRAS Mutation**                                                                                                      **0.012**
  Gly12Ala                          8 (12%)                                                  1 (1%)        2 (6%)        
      Gly12Asp                      20 (29%)                                                 31 (40%)      9 (27%)       
      Gly12Arg                      2 (3%)                                                   0 (0%)        1 (3%)        
      Gly12Cys                      9 (13%)                                                  5 (6%)        3 (9%)        
      Gly12Ser                      6 (9%)                                                   5 (6%)        3 (9%)        
      Gly12Val                      20 (29%)                                                 15 (19%)      5 (15%)       
  Gly13Asp                          4 (6%)                                                   21 (27%)      10 (30%)      
                                                                                                                         
  **BRAF Mutation Status**                                                                                               **\<0.001**
      Mutant                        9 (5%)                                                   24 (14%)      2 (2%)        
      Wildtype                      147 (86%)                                                133 (78%)     81 (90%)      
      Unknown                       14 (8%)                                                  14 (8%)       7 (8%)        

Proximal and distal colon tumors were demarcated by the splenic flexure. Rectal tumors were defined as those within 15 cm of the anal verge.

*P* value was based on Kruskal-Wallis Test for age and χ^2^ test for other characteristics. Patients with unknown characteristics were excluded.

###### 

ERCC1, TS, EGFR, VEGFR2 Gene Expression Levels by Tumor Site and KRAS Mutation Status

                                                  Primary Tumor Location                                                                                                                    
  ----------------------------------------------- ------------------------ ---------------------- --------------------- ---------------------- --------------------- ---------------------- ----------------------
  ERCC1                                           Mutant                   67                     0.79 (0.27 -- 2.96)   77                     0.82 (0.26 -- 2.95)   32                     0.96 (0.23 -- 2.60)
  Wildtype                                        86                       0.84 (0.17 -- 6.66)    79                    0.97 (0.28 -- 3.06)    46                    1.25 (0.37 -- 4.23)    
      *P* value[\*](#TFN3){ref-type="table-fn"}   0.80                     **0.005**              0.052                                                                                     
  All                                             162                      0.83 (0.17 -- 6.66)    162                   0.91 (0.26 -- 3.06)    88                    1.11 (0.23 -- 4.23)    
    Pairwise[‡](#TFN5){ref-type="table-fn"}       **×**                    √                      **×, √**                                                                                  
      *P* value[†](#TFN4){ref-type="table-fn"}    **0.001**                                                                                                                                 
  TS                                              Mutant                   67                     1.92 (0.81 -- 9.26)   76                     1.90 (0.52 -- 9.43)   31                     2.69 (0.77 -- 21.43)
  Wildtype                                        84                       2.25 (0.65 -- 10.02)   79                    2.38 (0.65 -- 13.81)   46                    2.66 (0.97 -- 18.99)   
      *P* value[\*](#TFN3){ref-type="table-fn"}   0.31                     **0.03**               0.80                                                                                      
  All                                             160                      2.12 (0.65 -- 10.26)   161                   2.18 (0.52 -- 13.81)   85                    2.60 (0.77 -- 21.43)   
    Pairwise[‡](#TFN5){ref-type="table-fn"}       **×**                                           **×**                                                                                     
      *P* value[†](#TFN4){ref-type="table-fn"}    **0.02**                                                                                                                                  
  EGFR                                            Mutant                   67                     1.60 (0.79 -- 5.24)   76                     1.60 (0.33 -- 7.17)   32                     1.66 (0.78 -- 4.08)
  Wildtype                                        88                       1.78 (0.63 -- 5.68)    76                    2.12 (0.63 -- 7.45)    44                    2.20 (0.80 -- 71.28)   
      *P* value[\*](#TFN3){ref-type="table-fn"}   0.11                     **\<0.001**            0.11                                                                                      
  All                                             164                      1.70 (0.60 -- 5.68)    161                   1.88 (0.33 -- 7.45)    83                    1.92 (0.75 -- 71.28)   
    Pairwise[‡](#TFN5){ref-type="table-fn"}                                                                                                                                                 
      *P* value[†](#TFN4){ref-type="table-fn"}    0.20                                                                                                                                      
  VEGFR2                                          Mutant                   42                     1.32 (0.25 -- 7.66)   50                     0.91 (0.24 -- 6.10)   25                     1.53 (0.23 -- 3.62)
  Wildtype                                        66                       1.21 (0.18 -- 6.64)    54                    1.29 (0.33 -- 5.94)    38                    2.21 (0.37 -- 13.00)   
      *P* value[\*](#TFN3){ref-type="table-fn"}   0.58                     **0.01**               **0.02**                                                                                  
  All                                             111                      1.23 (0.18 -- 7.66)    108                   1.10 (0.24 -- 6.10)    68                    1.77 (0.23 -- 13.00)   
    Pairwise[‡](#TFN5){ref-type="table-fn"}       **×**                    √                      **×, √**                                                                                  
      *P* value[†](#TFN4){ref-type="table-fn"}    **\<0.001**                                                                                                                               

Based on Wilcoxon two -- sample test for differences by KRAS mutation status in each tumor site.

Based on Kruskal-Wallis test for differences across tumor sites.

Based on Wilcoxon two -- sample test for pairwise differences by two tumor sites adjusting for multiple comparisons; includes patients with unknown KRAS mutation status. The same symbol represents a significant pairwise difference.

###### 

ERCC1, TS, EGFR, VEGFR2 Gene Expression Levels by KRAS and BRAF Mutation Status

                                                KRAS Mutation Status   BRAF Mutation Status                                                                                          
  --------------------------------------------- ---------------------- ---------------------- ------------- ----- -------------------- ---- -------------------- ------------- ----- --------------------
  ERCC1                                         176                    0.87 (0.23--2.96)                    211   0.98 (0.17--6.66)    35   0.94 (0.28--2.47)                  356   0.91 (0.20--6.66)
    *P* value[\*](#TFN6){ref-type="table-fn"}                                                 **0.01**                                                           0.35                
  TS                                            174                    2.08 (0.52--21.43)                   209   2.38 (0.65--18.99)   34   3.38 (1.01--13.81)                 352   2.17 (0.52--21.43)
    *P* value[\*](#TFN6){ref-type="table-fn"}                                                 **0.03**                                                           **\<0.001**         
  EGFR                                          175                    1.61 (0.33--7.17)                    208   2.06 (0.63--71.28)   33   2.20(1.12--3.50)                   349   1.75 (0.33--71.28)
    *P* value[\*](#TFN6){ref-type="table-fn"}                                                 **\<0.001**                                                        **0.002**           
  VEGFR2                                        117                    1.19 (0.23--7.66)                    158   1.35 (0.18--13.00)   26   1.48 (0.29--3.41)                  252   1.25 (0.18--13.0)
    *P* value[\*](#TFN6){ref-type="table-fn"}                                                 **0.003**                                                          0.64                

Based on Kruskal-Wallis test.
